Pharma's developing interest in stem cells.

Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.

[1]  P. Schultz,et al.  A role for chemistry in stem cell biology , 2004, Nature Biotechnology.

[2]  S. Brunskill,et al.  Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. , 2008, European heart journal.

[3]  D. Gibbons,et al.  Developing a case study model for successful translation of stem cell therapies. , 2010, Cell stem cell.

[4]  J. Mosca,et al.  T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. , 2005, Journal of biomedical science.

[5]  N. Flomenberg,et al.  Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[7]  Peter G Schultz,et al.  Small molecules that induce cardiomyogenesis in embryonic stem cells. , 2004, Journal of the American Chemical Society.

[8]  M. Al-mallah,et al.  Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[9]  S. Schreiber,et al.  A small molecule that directs differentiation of human ESCs into the pancreatic lineage. , 2009, Nature chemical biology.

[10]  V. Glaser.  Genetics Policy Institute , 2006 .

[11]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.